Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

Fig. 2

Incidence of ctDNA emerging alterations in patients with advanced cancer and treated with targeted therapy in the BIP study. (A) Incidence of ctDNA emerging alterations in patients with advanced colorectal cancer and receiving an anti-EGFR monoclonal antibody. (B) Kaplan-Meier curve of overall survival in colorectal cancer patients according to presence or not of at least one ctDNA emerging alteration. (C) Incidence of ctDNA emerging alterations in patients with advanced prostate cancer and receiving an anti-androgen hormonal therapy. (D) Kaplan-Meier curve of overall survival in prostate cancer patients according to presence or not of at least one ctDNA emerging alteration. (E) Incidence of ctDNA emerging alterations in patients with advanced breast cancer and receiving an anti-oestrogen hormonal therapy. (F) Kaplan-Meier curve of overall survival in breast cancer patients according to presence or not of at least one ctDNA emerging alteration (G) Incidence of ctDNA emerging alterations in patients with advanced non-small cell lung cancer and receiving an EGFR tyrosine kinase inhibitor. (H) Kaplan-Meier curve of overall survival in breast cancer patients according to presence or not of at least one ctDNA emerging alteration

Back to article page

Molecular Cancer

ISSN: 1476-4598